Table 2.

Effects of depleting donor SJL T cells after cell transfer into SJL-Thy1^a recipients

	Clinical Signs of Acute EAE
Treatment	Day of treatment	Disease incidence	Av. max. dis. grade (mean ± SEM)	Av. day dis. onset (mean ± SEM)
No treatment	-	13/14	3.5 ± 0.18	10.0 ± 0.30
Saline	−3, 0, +3	4/4	4.0 ± 0	8.5 ± 0.29
Isotype-matched Ig	−3, 0, +3	6/6	3.0 ± 0.26	9.5 ± 0.42
Anti-Thy-1.2	−3, 0, +3	0/12	--	--

Development of acute EAE after 2nd transfer of donor cells 60 days post anti-Thy-1.2 treatment
Cell transfer	Disease incidence	Av. max. dis. grade (mean ± SEM)	Av. day dis onset (mean ± SEM)
No cell transfer	0/6	--	--
With cell transfer	6/6	3.1 ± 0.27	8.3 ± 0.42

SJL mice were immunized with PLP_139–151 peptides emulsified in CFA. Ten days later, draining lymph nodes were removed and the cells were restimulated in vitro with the priming antigen for four days. Cells were harvested and 5 × 10⁷ viable cells were transferred into naïve SJL-Thy-1^a recipients through the tail vein. At days −3, 0 and +3 relative to cell transfer, recipient mice were treated with isotype-matched and anti-Thy-1.2 antibodies. Disease was monitored for 30 days. Anti-Thy-1.2 antibody-treated mice failed to develop acute adoptive EAE. 60 days later, these mice received a new batch of PLP_139–151-primed and in vitro-stimulated SJL donor lymph nodes cells i.v. Disease was monitored for 30 days.